-
公开(公告)号:US20130203756A1
公开(公告)日:2013-08-08
申请号:US13825616
申请日:2011-10-24
申请人: Jamie L. Bunda , Christopher D. Cox , Vadim Y. Dudkin , Hannah D. Fiji , Michael J. Kelly , Mark E. Layton , Joseph E. Pero , William D. Shipe , Justin T. Sheen
发明人: Jamie L. Bunda , Christopher D. Cox , Vadim Y. Dudkin , Hannah D. Fiji , Michael J. Kelly , Mark E. Layton , Joseph E. Pero , William D. Shipe , Justin T. Sheen
IPC分类号: C07D403/06 , C07D519/00 , C07D417/14 , C07D413/14 , C07D471/04
CPC分类号: C07D403/06 , A61K31/44 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
摘要: The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
摘要翻译: 本发明涉及可用作治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统疾病的治疗剂的异吲哚啉酮化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症,精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。